Terms: = Leukemia AND CCND1, BCL1, 595, ENSG00000110092, PRAD1, U21B31, D11S287E AND Treatment
111 results:
1. On the mechanism of wogonin against acute monocytic leukemia using network pharmacology and experimental validation.
Wang X; Wang Y; Chen J; Wang Q; Liu Z; Yin Y; Yang T; Shen T; Sa Y
Sci Rep; 2024 May; 14(1):10114. PubMed ID: 38698063
[TBL] [Abstract] [Full Text] [Related]
2. GLI1 polymorphisms influence remission rate and prognosis of young de novo acute myeloid leukemia patients treated with cytarabine-based chemotherapy.
Liu Y; Liu Y; Chen P; Chen G; Chen X
Ann Hematol; 2024 Jun; 103(6):1967-1977. PubMed ID: 38676765
[TBL] [Abstract] [Full Text] [Related]
3. Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH): a scoping review unveils clinical and diagnostic patterns of a lymphoma subgroup with poor prognosis.
Knauft J; Schenk T; Ernst T; Schnetzke U; Hochhaus A; La Rosée P; Birndt S
Leukemia; 2024 Feb; 38(2):235-249. PubMed ID: 38238443
[TBL] [Abstract] [Full Text] [Related]
4. [Mechanism of Proliferation and Apoptosis of Acute Promyelocytic leukemia Cell Line NB4 Induced by TPA].
Zhao P; Zhang C; Dong XM; Yan LW; Mi LY; Li YJ; Kang JC; Wang J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1296-1302. PubMed ID: 37846675
[TBL] [Abstract] [Full Text] [Related]
5. Illuminating (HTLV-1)-induced adult T-cell leukemia/lymphoma transcriptomic signature: A systems virology approach.
Forghani-Ramandi MM; Mostafavi B; Bahavar A; Dehghankar M; Siami Z; Mozhgani SH
Virus Res; 2023 Dec; 338():199237. PubMed ID: 37832654
[TBL] [Abstract] [Full Text] [Related]
6. CircPLXNB2 regulates acute myeloid leukemia progression through miR-654-3p/
Wang J; Wu C; Zhou W
Hematology; 2023 Dec; 28(1):2220522. PubMed ID: 37272581
[TBL] [Abstract] [Full Text] [Related]
7. Immunochemotherapy for life-threatening haematological malignancies in pregnancy: a systematic review of the literature and cross-sectional analysis of clinical trial eligibility.
Mills GS; Chadwick V; Tang C; Perram J; Anderson MA; Anazodo A; Kidson-Gerber G; Shand A; Lavee O; Withers B; Milliken S; Di Ciaccio PR; Hamad N
Lancet Haematol; 2023 Jun; 10(6):e458-e467. PubMed ID: 37263722
[TBL] [Abstract] [Full Text] [Related]
8. Adverse Reaction Profiles Related to Gastrointestinal Bleeding Events Associated with BCR-ABL Tyrosine Kinase Inhibitors.
Kawada K; Ishida T; Jobu K; Morisawa S; Tamura N; Sugimoto S; Okazaki M; Yoshioka S; Miyamura M
Medicina (Kaunas); 2022 Oct; 58(10):. PubMed ID: 36295654
[No Abstract] [Full Text] [Related]
9. Cost-effectiveness Analysis of Tisagenlecleucel Versus Blinatumomab in Children and Young Adults with Acute Lymphoblastic leukemia: Partitioned Survival Model to Assess the Impact of an Outcome-Based Payment Arrangement.
Gye A; Goodall S; De Abreu Lourenco R
Pharmacoeconomics; 2023 Feb; 41(2):175-186. PubMed ID: 36266557
[TBL] [Abstract] [Full Text] [Related]
10. Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial.
Freeman CL; Pararajalingam P; Jin L; Balasubramanian S; Jiang A; Xu W; Grau M; Zapukhlyak M; Boyle M; Hodkinson B; Schaffer M; Enny C; Deshpande S; Sun S; Vermeulen J; Morin RD; Scott DW; Lenz G
Leukemia; 2022 Oct; 36(10):2479-2487. PubMed ID: 35963941
[TBL] [Abstract] [Full Text] [Related]
11. Estimation of iron overload with T2*MRI in children treated for hematological malignancies.
Munikoty V; Sodhi KS; Bhatia A; Bhatia P; Verma Attri S; Rohit MK; Trehan A; Khandelwal N; Bansal D
Pediatr Hematol Oncol; 2023 May; 40(4):315-325. PubMed ID: 35833695
[TBL] [Abstract] [Full Text] [Related]
12.
Kayabasi C; Yilmaz Susluer S; Balci Okcanoglu T; Ozmen Yelken B; Mutlu Z; Goker Bagca B; Caliskan Kurt C; Saydam G; Durmuskahya C; Kayalar H; Ozbilgin A; Biray Avci C; Gunduz C
Nutr Cancer; 2022; 74(10):3679-3691. PubMed ID: 35608652
[No Abstract] [Full Text] [Related]
13. Oral oncolytic treatment for chronic lymphocytic leukemia.
Harris V; Borlagdan J; Muluneh B
J Oncol Pharm Pract; 2022 Jun; 28(4):935-944. PubMed ID: 35084245
[TBL] [Abstract] [Full Text] [Related]
14. Chronic Lymphocytic leukemia/Small Lymphocytic Lymphoma With Secondary Acquisition of t(11;14)(q13;q32)/ccnd1-IGH: A Rare Variant Of Richter Transformation to Mantle Cell Lymphoma.
Zhao Y; McCracken J; Rehder C; Wang E
Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e310-e313. PubMed ID: 34840090
[TBL] [Abstract] [Full Text] [Related]
15. Aberrantly reduced expression of miR-342-5p contributes to ccnd1-associated chronic myeloid leukemia progression and imatinib resistance.
Wu YY; Lai HF; Huang TC; Chen YG; Ye RH; Chang PY; Lai SW; Chen YC; Lee CH; Liu WN; Dai MS; Chen JH; Ho CL; Chiu YL
Cell Death Dis; 2021 Oct; 12(10):908. PubMed ID: 34611140
[TBL] [Abstract] [Full Text] [Related]
16. Twists and turns from "tumor in tumor" profiling: surveillance of chronic lymphocytic leukemia (CLL) leads to detection of a lung adenocarcinoma, whose genomic characterization alters the original hematologic diagnosis.
Terraf P; Sholl LM; Davids MS; Awad MM; Garcia EP; MacConaill LE; Dal Cin P; Kim A; Lindeman NI; Stachler M; Hwang DH; Dubuc AM
Cold Spring Harb Mol Case Stud; 2021 Aug; 7(4):. PubMed ID: 34074652
[TBL] [Abstract] [Full Text] [Related]
17. Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia.
Patel KK; Zeidan AM; Shallis RM; Prebet T; Podoltsev N; Huntington SF
Blood Adv; 2021 Feb; 5(4):994-1002. PubMed ID: 33591323
[TBL] [Abstract] [Full Text] [Related]
18. Whole transcriptome sequencing and integrated network analysis elucidates the effects of 3,8-Di-O-methylellagic acid 2-O-glucoside derived from Sanguisorba offcinalis L., a novel differentiation inducer on erythroleukemia cells.
Long W; Liu S; Li XX; Shen X; Zeng J; Luo JS; Li KR; Wu AG; Yu L; Qin DL; Hu GQ; Yang J; Wu JM
Pharmacol Res; 2021 Apr; 166():105491. PubMed ID: 33582247
[TBL] [Abstract] [Full Text] [Related]
19. Haploidentical hematopoietic stem cell transplantation for patients with myeloid sarcoma: a single center retrospective study.
Yu WJ; Sun YQ; Han TT; Ye PP; Zhang XH; Xu LP; Liu KY; Yan CH; Huang XJ; Wang Y
Ann Hematol; 2021 Mar; 100(3):799-808. PubMed ID: 33416901
[TBL] [Abstract] [Full Text] [Related]
20. TCF7 knockdown inhibits the imatinib resistance of chronic myeloid leukemia K562/G01 cells by neutralizing the Wnt/β‑catenin/TCF7/ABC transporter signaling axis.
Zhang H; Wang Y; Yang H; Huang Z; Wang X; Feng W
Oncol Rep; 2021 Feb; 45(2):557-568. PubMed ID: 33416164
[TBL] [Abstract] [Full Text] [Related]
[Next]
